|Gross Div Yield||0.000%|
Biotechnology company, specialising diagnosis and characterisation of diseases.
There are no upcoming dividends in this security at this time.
|Ongoing Disclosure Notice - Anatole Masfen||12 Mar 2014, 2:43pm||RELINT|
|NZXR Price Enquiry into Pacific Edge Limited ("...||11 Mar 2014, 4:02pm||S/PRICE|
|Ongoing Disclosure Notice - D Darling||10 Mar 2014, 4:46pm||RELINT|
|Ongoing Disclosure Notice - Christopher Swann||7 Mar 2014, 12:14pm||RELINT|
|SSH Notice - Peter Karl Christopher Huljich||6 Mar 2014, 2:13pm||SSH|
Pacific Edge Limited (PEB) was formed in August 2001 following acquisition of intellectual property from the University of Otago. The company is involved in the development of tools for early detection, diagnosis and characterisation of diseases, particularly cancer. It plans to develop sophisticated diagnostic and screening tools based ...(more)
This information was provided by Pacific Edge Limited in their Half Year Report released on 29 November 2013: The Company has recorded a net loss, from investment in its commercial developments including : market entry, research and product development, of $4,971,183 for the half year ended 30 September 2013, compared to a budgeted lo...(more)